Group 1 - The core point of the article is that Haichuang Pharmaceutical (SH 688302) held its 16th meeting of the second board on December 24, 2025, to discuss various proposals, including the exemption of the notice period for the meeting [1] - For the first half of 2025, Haichuang Pharmaceutical's revenue composition was 99.25% from pharmaceuticals and 0.75% from materials and R&D intermediates [1] - As of the report date, Haichuang Pharmaceutical has a market capitalization of 5.1 billion yuan [1] Group 2 - The article also mentions Yang Lingjiang's acquisition of a leading domestic winery, raising questions about the potential relisting of 1919 [1] - There is a sense of urgency expressed regarding the achievement of a target of 100 billion yuan, indicating pressure on the company to meet its financial goals [1]